Expert Interview
Discussing Cabaletta Bio's rese-cel (resecabtagene autoleucel) for patients with myositis, lupus and systemic sclerosis and the data from the the ongoing RESET trials.
Ticker(s): CABAInstitution: Stanford & Private Practice
- Rheumatologist, Adjunct Clinical Professor, Division of Immunology and Rheumatology at Stanford University, and consultant in clinical research and regulatory affairs.
- Interests include translation of basic research into rational design of randomized controlled trials, analysis of their results and presentation of novel products for approval to FDA and EMA.
- Has assisted in preparation of briefing documents, analyses and data presentation for defense of NDA and BLA applications in RA, SLE, PsA, SpA, SSc, uveitis, OA, gout, FMS and the first monoclonal antibody biosimilar.
- Established and co-chaired the biyearly “Innovative Therapies in Autoimmune Disease” meetings co-sponsored by ACR, NIH and FDA, and has authored over 335 original publications.
How do you view the potential of CD19-directed cell therapy like rese-cel in autoimmune diseases such as myositis, lupus, and systemic sclerosis—particularly compared to B-cell depletion strategies like rituximab?
Added By: sara_adminBased on data from the RESET trials, what are your impressions regarding the durability and depth of response observed so far in these heavily pre-treated autoimmune patients?
Added By: sara_adminIf rese-cel continues to show promise, how do you see it fitting into future treatment paradigms for autoimmune diseases—would it be reserved for refractory cases, or could it move earlier in the treatment algorithm over time
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
